drugset / Trial / NCT03365791
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
Timeline
- Start
- 2018-01-24
- Primary completion
- 2019-02-21
- Completion
- 2020-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spartalizumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | ieramilimab | Monoclonal antibody | 400 mg | Intravenous |